3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Hodgkin Disease
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Lymphoma, T-Cell
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma
1
Hematologic Diseases
1
Interventions
Rituximab
6
Lenalidomide
3
Bendamustine Hydrochloride
3
pirtobrutinib
2
Cyclophosphamide
2
venetoclax
1
umbralisib
1
ublituximab
1
tocilizumab
1
obinutuzumab
1
idelalisib
1
glofitamab
1
fludarabine
1
atezolizumab
1
acalabrutinib
1
Vincristine
1
Standard of Care
1
Prednisone
1
Doxorubicin
1
Brentuximab Vedotin
1
Appointments and Schedules
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has announcements
×
Lymphoma, Non-Hodgkin
×
Brentuximab Vedotin
×
Clear all
NCT01777152
2021-11-30
ECHELON-2
Seagen Inc.
Phase 3
Completed
452 enrolled
16 charts
1 FDA